Q-omics provides the consensus-scored LINC01684 profile across patient tissues and cancer cell-line models. LINC01684 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, LINC01684 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, LINC01684 RNA expression shows 16,578 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight SKCM, KIRC, and LSCC as cancer lineages where LINC01684 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01684 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01684 survival associations across molecular data types. LINC01684 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01684 RNA expression–survival associations across cancer types. High LINC01684 expression shows unfavorable associations in MESO, LGG, READ and KIRC, but favorable associations in SKCM and HNSC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for LINC01684 RNA expression.
This table summarizes LINC01684 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01684. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01684 shows lower tumor expression in UCEC, KICH and LUSC and higher tumor expression in KIRC, HNSC and STAD. The KIRC box plot shows higher LINC01684 RNA expression in tumor versus normal tissue (log2 FC = +0.297, t-test p < 0.001).
This table shows molecular features associated with LINC01684 in patient tissues and cancer cell lines. In patient samples, LINC01684 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
